The role of fibrate treatment in dyslipidemia: an overview.
about
Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic SyndromeP2Y13 receptor regulates HDL metabolism and atherosclerosis in vivoIs statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate.The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.Critical review of non-statin treatments for dyslipoproteinemia.Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease.Dyslipidaemia and the military patient.Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.An update on PPAR activation by cannabinoids.Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention.Chalcone Derivatives: Promising Starting Points for Drug Design.Evaluating bempedoic acid for the treatment of hyperlipidaemia.The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transportCytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines.Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.Management of Statin Intolerance in 2018: Still More Questions Than Answers.Pharmacological Intervention to Modulate HDL: What Do We Target?Dyslipidaemia in the elderly: to treat or not to treat?Emerging approaches for the treatment of hypertriglyceridemia.Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease
P2860
Q26801281-9FFA0892-147A-4CAF-912B-C4238BAED6AAQ35158162-93BDCF58-99A1-4B5A-9966-2CD6F68372B2Q35894747-389503C5-CB69-47AD-BAFA-10D744C5CC77Q37304485-296C86B3-157D-423F-A936-3F6F84CC2EC8Q38186099-970DF8AA-7923-4AFC-B5EB-F030D8E1B08EQ38188874-A4E41E9C-5C81-4645-9E6E-A7275DB8EEC9Q38561477-E8CD528C-88E0-46C3-9E57-1F910426A06BQ38631018-59791C06-CA88-4E0F-9E2E-47D46C2B7DD0Q38674742-F3B33644-7C60-4ADE-BCC3-831E2C168AA1Q38808034-2C5C5E55-CC6E-44A7-939A-F99887282BDAQ39004398-A042D03F-FBF4-4BC0-8B7B-181DF315371BQ39027317-5E7F0C19-32B6-4B02-B7D2-5CE8412EFA2DQ39074339-6ACB78B5-8CF5-4B8C-9A5E-9C9EE09029B0Q39185669-5FDC324D-AAF9-47C5-B9A8-C6C04C2787B2Q39399592-85B15CF0-DAF8-4AD2-ABE2-59B505939EC4Q39420208-CF648199-C9C2-4D33-8701-21C93FC1AAAEQ41975402-B3E4BCC5-24E1-4E3F-A039-441F149306E4Q43974650-95D9D2EE-D2B7-4E47-B129-D97E11DE9E2CQ45895181-D5408B17-F7BA-4AA8-A570-503D9DC3F687Q48274059-4E8E0256-C376-433F-806E-ECFE8BE38553Q49554117-8B745AA4-2D96-4528-AA3B-F88C7570ECE0Q50180407-A47D200C-0471-4910-8546-6622CCEC5D49Q51334679-0327BAB5-51DD-41A5-8E83-986598A621DEQ59135837-CCEC1411-984E-4B0E-AF59-F924671B3646
P2860
The role of fibrate treatment in dyslipidemia: an overview.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of fibrate treatment in dyslipidemia: an overview.
@en
type
label
The role of fibrate treatment in dyslipidemia: an overview.
@en
prefLabel
The role of fibrate treatment in dyslipidemia: an overview.
@en
P50
P1476
The role of fibrate treatment in dyslipidemia: an overview.
@en
P2093
Niki Katsiki
P304
P356
10.2174/1381612811319170020
P577
2013-01-01T00:00:00Z